{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:01:31Z","timestamp":1792011691215,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease (FD) is an X-linked inherited storage disorder caused by deficiency of lysosomal alpha-Galactosidase A. Here we describe new retinal findings in patients with FD assessed by Spectral domain optical coherence tomography\u00a0(SD-OCT) and their possible clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>54 eyes of 27 FD patients and 54 eyes of 27 control subjects were included. The ophthalmic examination included visual acuity testing, tonometry, slit lamp and fundus examination. SD-OCT imaging of the macula was performed in all subjects. Central retinal thickness and retinal nerve fiber layer analysis were quantified. Vessel tortuosity was obtained by a subjective scoring and mathematically calculated. Inner retinal hyperreflective foci (HRF) were quantified, clinically graded and correlated with a biomarker of Fabry disease (lyso-Gb3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In comparison to an age-matched control group, a significant amount of HRF was identified in macular SD-OCT images in FD patients. These HRF were localized within the inner retinal layers. Furthermore, lyso-Gb3 levels correlated significantly with the quantitative evaluation of HRF (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090,001). In addition, the vessel tortuosity was remarkably increased in FD patients compared to control persons and correlated significantly with lyso-G3 levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). A further subanalysis revealed significantly higher HRF and vessel tortuosity scores in male patients with the classic FD phenotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The observational, cross sectional, comparative study describes novel intraretinal findings in patients with FD. We were able to identify suspicious HRF within the inner retinal layers. These findings were not accompanied by functional limitations, as visual acuity remained unchanged. However, HRF correlated well with lyso-Gb3, a degradation product of the accumulating protein Gb3 and might potentially indicate Gb3 accumulation within the highly metabolic and densely vascularized macula.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-019-1267-2","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T11:02:24Z","timestamp":1577358144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Retinal hyperreflective foci in Fabry disease"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-0478","authenticated-orcid":false,"given":"Yevgeniya","family":"Atiskova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman","family":"Rassuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Friederike","family":"Koehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Golsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wagenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"du Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,26]]},"reference":[{"issue":"1","key":"1267_CR1","first-page":"393","volume":"16","author":"RJ Desnick","year":"1980","unstructured":"Desnick RJ, Dean KJ, Grabowski GA, Bishop DF, Sweeley CC. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease. Birth Defects Orig Artic Ser. 1980;16(1):393\u2013413.","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"1\u20132","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344(1\u20132):5\u201319.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1267_CR3","first-page":"37","volume":"5","author":"C Ellaway","year":"2016","unstructured":"Ellaway C. Paediatric Fabry disease. Transl Pediatr. 2016;5(1):37\u201342.","journal-title":"Transl Pediatr"},{"issue":"5263","key":"1267_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/2271173b0","volume":"227","author":"JA Kint","year":"1970","unstructured":"Kint JA. The enzyme defect in Fabry\u2019s disease. Nature. 1970;227(5263):1173.","journal-title":"Nature."},{"issue":"5","key":"1267_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64(5):550\u20135.","journal-title":"Pediatr Res"},{"key":"1267_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/mgg3.389","volume":"6","author":"DP Germain","year":"2018","unstructured":"Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6:492.","journal-title":"Mol Genet Genomic Med"},{"issue":"1\u20132","key":"1267_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","volume":"119","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry registry. Mol Genet Metab. 2016;119(1\u20132):151\u20139.","journal-title":"Mol Genet Metab"},{"issue":"29","key":"1267_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007387","volume":"96","author":"JH Choi","year":"2017","unstructured":"Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype. Medicine (Baltimore). 2017;96(29):e7387.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000479895","volume":"138","author":"VSP Veloso","year":"2018","unstructured":"Veloso VSP, Ataides TL, Canziani MEF, Veloso MP, da Silva NA, Barreto DV, et al. A novel missense GLA mutation (p.G35V) detected in hemodialysis screening leads to severe systemic manifestations of Fabry disease in men and women. Nephron. 2018;138(2):147\u201356.","journal-title":"Nephron."},{"issue":"7","key":"1267_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","volume":"2","author":"JP Davies","year":"1993","unstructured":"Davies JP, Winchester BG, Malcolm S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet. 1993;2(7):1051\u20133.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1267_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/cge.13007","volume":"92","author":"M du Moulin","year":"2017","unstructured":"du Moulin M, Koehn AF, Golsari A, Dulz S, Atiskova Y, Patten M, et al. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin Genet. 2017;92(5):528\u201333.","journal-title":"Clin Genet"},{"issue":"1","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-017-0810-9","volume":"17","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Hsu TR, Hung SC, Yu WC, Chu TH, Yang CF, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>a mutation. BMC Neurol. 2017;17(1):25.","journal-title":"BMC Neurol"},{"issue":"9","key":"1267_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539\u201348.","journal-title":"Genet Med"},{"issue":"2\u20133","key":"1267_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","volume":"84","author":"MJ Hilz","year":"2000","unstructured":"Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84(2\u20133):361\u20135.","journal-title":"Pain."},{"issue":"11","key":"1267_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162(11):767\u201372.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"1267_CR16","first-page":"246","volume":"76","author":"KJ Sheth","year":"1981","unstructured":"Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry\u2019s disease. Am J Gastroenterol. 1981;76(3):246\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1267_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Torra R, Lager DJ. Fabry disease: an underrecognized cause of proteinuria. Kidney Int. 2008;73(10):1193\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int. 1978;13(3):223\u201335.","journal-title":"Kidney Int"},{"issue":"7","key":"1267_CR19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102\u201311.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28(10):1228\u201335.","journal-title":"Eur Heart J"},{"issue":"1","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","volume":"63","author":"M Senechal","year":"2003","unstructured":"Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet. 2003;63(1):46\u201352.","journal-title":"Clin Genet"},{"issue":"6","key":"1267_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","volume":"96","author":"JS Shah","year":"2005","unstructured":"Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96(6):842\u20136.","journal-title":"Am J Cardiol"},{"issue":"9","key":"1267_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","volume":"5","author":"A Fellgiebel","year":"2006","unstructured":"Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry\u2019s disease. Lancet Neurol. 2006;5(9):791\u20135.","journal-title":"Lancet Neurol"},{"issue":"11","key":"1267_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med"},{"key":"1267_CR25","volume-title":"Fabry disease: perspectives from 5 years of FOS. Oxford","author":"M Beck","year":"2006","unstructured":"Beck M. Demographics of FOS - the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford; 2006."},{"key":"1267_CR26","unstructured":"Ramaswami U, Parini R, Pintos-Morell G. Natural history and effects of enzyme replacement therapy in children and adolescents with Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 31."},{"issue":"21","key":"1267_CR27","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA."},{"issue":"4","key":"1267_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","volume":"53","author":"N Samiy","year":"2008","unstructured":"Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol. 2008;53(4):416\u201323.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"1267_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","volume":"100","author":"L van der Tol","year":"2016","unstructured":"van der Tol L, Sminia ML, Hollak CE, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100(1):3\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1267_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry\u2019s disease: data from the Fabry outcome survey. Br J Ophthalmol. 2007;91(2):210\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1267_CR31","doi-asserted-by":"publisher","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS One. 2015;10(3):e0120814.","journal-title":"PLoS One"},{"issue":"3","key":"1267_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/IAE.0000000000001177","volume":"37","author":"I San Roman","year":"2017","unstructured":"San Roman I, Rodriguez ME, Caporossi O, Zoppetti C, Sodi A, Mecocci A, et al. Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina. 2017;37(3):592\u2013603.","journal-title":"Retina."},{"issue":"2","key":"1267_CR33","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/j.1755-3768.2012.02576.x","volume":"91","author":"A Sodi","year":"2013","unstructured":"Sodi A, Guarducci M, Vauthier L, Ioannidis AS, Pitz S, Abbruzzese G, et al. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease. Acta Ophthalmol. 2013;91(2):e113\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"1267_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1442-9071.2005.00990.x","volume":"33","author":"TT Nguyen","year":"2005","unstructured":"Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol. 2005;33(2):164\u20138.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"1267_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"Hitoshi Sakuraba","year":"2017","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2017;22(4):843\u201349.","journal-title":"Clinical and Experimental Nephrology"},{"issue":"10","key":"1267_CR36","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0161-6420(84)34165-3","volume":"91","author":"RG Orlando","year":"1984","unstructured":"Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 1984;91(10):1184\u20137.","journal-title":"Ophthalmology."},{"key":"1267_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/OPTH.S58164","volume":"8","author":"M Kuroda","year":"2014","unstructured":"Kuroda M, Hirami Y, Hata M, Mandai M, Takahashi M, Kurimoto Y. Intraretinal hyperreflective foci on spectral-domain optical coherence tomographic images of patients with retinitis pigmentosa. Clin Ophthalmol. 2014;8:435\u201340.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1267_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116(5):914\u201320.","journal-title":"Ophthalmology."},{"issue":"4","key":"1267_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ophtha.2009.09.027","volume":"117","author":"GG Deak","year":"2010","unstructured":"Deak GG, Bolz M, Kriechbaum K, Prager S, Mylonas G, Scholda C, et al. Effect of retinal photocoagulation on intraretinal lipid exudates in diabetic macular edema documented by optical coherence tomography. Ophthalmology. 2010;117(4):773\u20139.","journal-title":"Ophthalmology."},{"issue":"9","key":"1267_CR40","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1167\/iovs.12-9950","volume":"53","author":"C Framme","year":"2012","unstructured":"Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53(9):5814\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1267_CR41","doi-asserted-by":"crossref","unstructured":"Parodi MB, Romano F, Sacconi R, Casati S, Marchini G, Bandello F, et al. Intraretinal hyperreflective foci in best vitelliform macular dystrophy. Retina. 2017.","DOI":"10.1097\/IAE.0000000000001893"},{"issue":"1","key":"1267_CR42","first-page":"014002","volume":"5","author":"IP Okuwobi","year":"2018","unstructured":"Okuwobi IP, Fan W, Yu C, Yuan S, Liu Q, Zhang Y, et al. Automated segmentation of hyperreflective foci in spectral domain optical coherence tomography with diabetic retinopathy. J Med Imaging (Bellingham). 2018;5(1):014002.","journal-title":"J Med Imaging (Bellingham)"},{"issue":"3","key":"1267_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","volume":"24","author":"C Orssaud","year":"2003","unstructured":"Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003;24(3):129\u201339.","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"1267_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/archopht.1979.01020010327008","volume":"97","author":"NA Sher","year":"1979","unstructured":"Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol. 1979;97(4):671\u20136.","journal-title":"Arch Ophthalmol"},{"key":"1267_CR45","unstructured":"Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford; 2006."},{"issue":"2","key":"1267_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123(2):148\u201353.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1267_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-017-0152-7","volume":"18","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients. BMC Pharmacol Toxicol. 2017;18(1):43.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"1267_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121(2):157\u201361.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"1267_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1\u20132):57\u201361.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1267_CR50","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105(8):2812\u20137.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1267-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T19:22:21Z","timestamp":1608837741000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1267-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1267-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the medical ethics committee of the \u00c4rztekammer Hamburg, Germany and followed the tenets of the declaration of Helsinki for research involving human subjects.Ethical committee approval No. PV5470.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from all participants of the study using institutional consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}